Datasets:

dennlinger

/

wiki-paragraphs

like 0

Temple University's College of Public Health offers a Master of Science in Clinical Research and Translational Medicine. The program is jointly offered with the Lewis Katz School of Medicine.

In Fall 2015, the City College of New York established a master in translational medicine program. A partnership between The Grove School of Engineering and the Sophie Davis School for Biomedical Education/CUNY School of Medicine, this program provides scientists, engineers, and pre-med students with training in product design, intellectual property, regulatory affairs, and medical ethics over 3 semesters.

Temple University's College of Public Health offers a Master of Science in Clinical Research and Translational Medicine. The program is jointly offered with the Lewis Katz School of Medicine.

Academy of Translational Medicine Professionals (ATMP) offers fellowship program which is open to highly experienced professionals who have a record of significant achievements in benchside, bedside or community health fields.

Temple University's College of Public Health offers a Master of Science in Clinical Research and Translational Medicine. The program is jointly offered with the Lewis Katz School of Medicine.

In 2010, UC Berkeley and UC San Francisco used a founding grant from Andy Grove to launch a joint program that became the Master of Translational Medicine. The program links the Bioengineering department at Berkeley with the Bioengineering and Therapeutic Science department at UCSF to give students a one-year experience in fostering medical innovation.

Temple University's College of Public Health offers a Master of Science in Clinical Research and Translational Medicine. The program is jointly offered with the Lewis Katz School of Medicine.

Translational medicine (often referred to as translational science, of which it is a form) is defined by the European Society for Translational Medicine (EUSTM) as "an interdisciplinary branch of the biomedical field supported by three main pillars: benchside, bedside, and community". The goal of TM is to combine disciplines, resources, expertise, and techniques within these pillars to promote enhancements in prevention, diagnosis, and therapies. Accordingly, translational medicine is a highly interdisciplinary field, the primary goal of which is to coalesce assets of various natures within the individual pillars in order to improve the global healthcare system significantly.

Mahidol University at Faculty of Medicine Ramathibodi hospital has a Master and PhD programme in Translational Medicine since 2012. Mahidol University is the first University in Thailand and in Southeast Asia. The most of programme lecturers are physicians and clinicians who contribute in many fields of study such as Cancer, Allergy and Immunology, Haematology, Paediatric, Rheumatology, etc. Here, the student will be directly exposed to patients. To find out the thing in between basic science and clinical application.

Cedars-Sinai Medical Center in Los Angeles, California was accredited in 2012 for a doctoral program in Biomedical Science and Translational Medicine. The PhD program focuses on biomedical and clinical research that relate directly to developing new therapies for patients.

Mahidol University at Faculty of Medicine Ramathibodi hospital has a Master and PhD programme in Translational Medicine since 2012. Mahidol University is the first University in Thailand and in Southeast Asia. The most of programme lecturers are physicians and clinicians who contribute in many fields of study such as Cancer, Allergy and Immunology, Haematology, Paediatric, Rheumatology, etc. Here, the student will be directly exposed to patients. To find out the thing in between basic science and clinical application.

Academy of Translational Medicine Professionals (ATMP) is working to advance the ongoing knowledge and skills for clinicians and scientific professionals at all levels. Academy’s high quality, standard and ethical training and educational programs ensure that all clinical and scientific professionals achieve excellence in their respective fields. Programs are accredited by the European Society for Translational Medicine (EUSTM).

Mahidol University at Faculty of Medicine Ramathibodi hospital has a Master and PhD programme in Translational Medicine since 2012. Mahidol University is the first University in Thailand and in Southeast Asia. The most of programme lecturers are physicians and clinicians who contribute in many fields of study such as Cancer, Allergy and Immunology, Haematology, Paediatric, Rheumatology, etc. Here, the student will be directly exposed to patients. To find out the thing in between basic science and clinical application.

The University of Edinburgh has been running an MSc in Translational Medicine program since 2007. It is a 3-year online distance learning programme aimed at the working health professional.

Mahidol University at Faculty of Medicine Ramathibodi hospital has a Master and PhD programme in Translational Medicine since 2012. Mahidol University is the first University in Thailand and in Southeast Asia. The most of programme lecturers are physicians and clinicians who contribute in many fields of study such as Cancer, Allergy and Immunology, Haematology, Paediatric, Rheumatology, etc. Here, the student will be directly exposed to patients. To find out the thing in between basic science and clinical application.

The European Society for Translational Medicine (EUSTM) is a global non-profit and neutral healthcare organization whose principal objective is to enhance world-wide healthcare by using translational medicine approaches, resources and expertise.

Mahidol University at Faculty of Medicine Ramathibodi hospital has a Master and PhD programme in Translational Medicine since 2012. Mahidol University is the first University in Thailand and in Southeast Asia. The most of programme lecturers are physicians and clinicians who contribute in many fields of study such as Cancer, Allergy and Immunology, Haematology, Paediatric, Rheumatology, etc. Here, the student will be directly exposed to patients. To find out the thing in between basic science and clinical application.

University of Liverpool, King's College London, Imperial College London, University College London, St George's, University of London, Oxford and Cambridge Universities run post-graduate courses in Translational Medicine too.

Mahidol University at Faculty of Medicine Ramathibodi hospital has a Master and PhD programme in Translational Medicine since 2012. Mahidol University is the first University in Thailand and in Southeast Asia. The most of programme lecturers are physicians and clinicians who contribute in many fields of study such as Cancer, Allergy and Immunology, Haematology, Paediatric, Rheumatology, etc. Here, the student will be directly exposed to patients. To find out the thing in between basic science and clinical application.

In recent years, a number of educational programs have emerged to provide professional training in the skills necessary for successfully translating research into improved clinical outcomes. These programs go by various names (including Master of Translational Medicine and Master of Science in Bioinnovation). Many such programs emerge from bioengineering departments, often in collaboration with clinical departments.

Suranaree University of Technology is the second University in Thailand and in Southeast Asia that has a Master and PhD programme in Translational Medicine (MSc 2018 and PhD 2019). MSc and PhD programmes are conducted by Institute of Medicine that contributed by phicians and PhD staffs which are focused in related field of benchside, bedside and community mainly parasites, Bacteria, cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international curriculum that supported by research centers in the university such as Parasitic Disease Research Center (PDRC), Helicobacter pylori and Gastric Cancer Researc Unit, Center of Excellent for Biomedical Engineering, Department of Research Affiare, Institute of Medicine, and Suranaree University of Technology Hospital. These programme will be faciltate students synthesize, analyses and integrate the basic medical science and clinical science for their professional work related to translational medicine. In addition, students will be understand the research process, innovation, and collaboration with multidisciplinary teams for solving health problems.

Since 2013, the Official Master in Translational Medicine-MSc from the University of Barcelona offers the opportunity to gain an excellent training through theoretical and practical courses. Furthermore, this master is linked to the doctoral programme “Medicine and Translational Research”, with quality mention from the National Agency for the Quality Evaluation and Accreditation (ANECA).

Suranaree University of Technology is the second University in Thailand and in Southeast Asia that has a Master and PhD programme in Translational Medicine (MSc 2018 and PhD 2019). MSc and PhD programmes are conducted by Institute of Medicine that contributed by phicians and PhD staffs which are focused in related field of benchside, bedside and community mainly parasites, Bacteria, cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international curriculum that supported by research centers in the university such as Parasitic Disease Research Center (PDRC), Helicobacter pylori and Gastric Cancer Researc Unit, Center of Excellent for Biomedical Engineering, Department of Research Affiare, Institute of Medicine, and Suranaree University of Technology Hospital. These programme will be faciltate students synthesize, analyses and integrate the basic medical science and clinical science for their professional work related to translational medicine. In addition, students will be understand the research process, innovation, and collaboration with multidisciplinary teams for solving health problems.

James Lind Institute has been conducting a Postgraduate Diploma in Translational Medicine since early 2013. The program has been supported by the Universiti Sains Malaysia.

Suranaree University of Technology is the second University in Thailand and in Southeast Asia that has a Master and PhD programme in Translational Medicine (MSc 2018 and PhD 2019). MSc and PhD programmes are conducted by Institute of Medicine that contributed by phicians and PhD staffs which are focused in related field of benchside, bedside and community mainly parasites, Bacteria, cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international curriculum that supported by research centers in the university such as Parasitic Disease Research Center (PDRC), Helicobacter pylori and Gastric Cancer Researc Unit, Center of Excellent for Biomedical Engineering, Department of Research Affiare, Institute of Medicine, and Suranaree University of Technology Hospital. These programme will be faciltate students synthesize, analyses and integrate the basic medical science and clinical science for their professional work related to translational medicine. In addition, students will be understand the research process, innovation, and collaboration with multidisciplinary teams for solving health problems.

Mahidol University at Faculty of Medicine Ramathibodi hospital has a Master and PhD programme in Translational Medicine since 2012. Mahidol University is the first University in Thailand and in Southeast Asia. The most of programme lecturers are physicians and clinicians who contribute in many fields of study such as Cancer, Allergy and Immunology, Haematology, Paediatric, Rheumatology, etc. Here, the student will be directly exposed to patients. To find out the thing in between basic science and clinical application.

Suranaree University of Technology is the second University in Thailand and in Southeast Asia that has a Master and PhD programme in Translational Medicine (MSc 2018 and PhD 2019). MSc and PhD programmes are conducted by Institute of Medicine that contributed by phicians and PhD staffs which are focused in related field of benchside, bedside and community mainly parasites, Bacteria, cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international curriculum that supported by research centers in the university such as Parasitic Disease Research Center (PDRC), Helicobacter pylori and Gastric Cancer Researc Unit, Center of Excellent for Biomedical Engineering, Department of Research Affiare, Institute of Medicine, and Suranaree University of Technology Hospital. These programme will be faciltate students synthesize, analyses and integrate the basic medical science and clinical science for their professional work related to translational medicine. In addition, students will be understand the research process, innovation, and collaboration with multidisciplinary teams for solving health problems.

The society facilitates cooperation and interaction among clinicians, scientists, academia, industry, governments, funding and regulatory agencies, investors and policy makers in order to develop and deliver high quality translational medicine programs and initiatives with overall aim to enhance the healthcare of global population. The society׳s goal is to enhance research and development of novel and affordable diagnostic tools and treatments for the clinical disorders affecting global population.

Suranaree University of Technology is the second University in Thailand and in Southeast Asia that has a Master and PhD programme in Translational Medicine (MSc 2018 and PhD 2019). MSc and PhD programmes are conducted by Institute of Medicine that contributed by phicians and PhD staffs which are focused in related field of benchside, bedside and community mainly parasites, Bacteria, cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international curriculum that supported by research centers in the university such as Parasitic Disease Research Center (PDRC), Helicobacter pylori and Gastric Cancer Researc Unit, Center of Excellent for Biomedical Engineering, Department of Research Affiare, Institute of Medicine, and Suranaree University of Technology Hospital. These programme will be faciltate students synthesize, analyses and integrate the basic medical science and clinical science for their professional work related to translational medicine. In addition, students will be understand the research process, innovation, and collaboration with multidisciplinary teams for solving health problems.

The Erasmus+ International Master in Innovative Medicine (IMIM) https://www.innovativemedicine.eu/ is a master of excellence programme, which focuses on the education of tomorrow’s leading translational biomedical researchers. The IMIM mission is to educate this future generation of translational scientists and professionals and to equip them with the skills and competences to work effectively, and to excel, in a wide range of multi- and interdisciplinary, internationally competitive academic and private sector environments. IMIM is jointly organised by three European Top 100 Universities: University of Groningen in the Netherlands, Heidelberg University in Germany and Uppsala University in Sweden. IMIM students will benefit from the vast wealth of resources and staff experience that these three universities have to offer in the biomedical sciences, as well as from their networks within both the academic and private sectors.         

Suranaree University of Technology is the second University in Thailand and in Southeast Asia that has a Master and PhD programme in Translational Medicine (MSc 2018 and PhD 2019). MSc and PhD programmes are conducted by Institute of Medicine that contributed by phicians and PhD staffs which are focused in related field of benchside, bedside and community mainly parasites, Bacteria, cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international curriculum that supported by research centers in the university such as Parasitic Disease Research Center (PDRC), Helicobacter pylori and Gastric Cancer Researc Unit, Center of Excellent for Biomedical Engineering, Department of Research Affiare, Institute of Medicine, and Suranaree University of Technology Hospital. These programme will be faciltate students synthesize, analyses and integrate the basic medical science and clinical science for their professional work related to translational medicine. In addition, students will be understand the research process, innovation, and collaboration with multidisciplinary teams for solving health problems.

In recent years, a number of educational programs have emerged to provide professional training in the skills necessary for successfully translating research into improved clinical outcomes. These programs go by various names (including Master of Translational Medicine and Master of Science in Bioinnovation). Many such programs emerge from bioengineering departments, often in collaboration with clinical departments.

University of Würzburg started a Master programme in Translational Medicine in 2018. It is aimed at medical students in the third or fourth year pursuing a career as a Clinician Scientist.

A master's degree programme in translational medicine was started at the University of Helsinki in 2010.

University of Würzburg started a Master programme in Translational Medicine in 2018. It is aimed at medical students in the third or fourth year pursuing a career as a Clinician Scientist.

The National Institutes of Health (NIH) has made a major push to fund translational medicine, especially within biomedical research, with a focus on cross-functional collaborations (e.g., between researchers and clinicians); leveraging new technology and data analysis tools; and increasing the speed at which new treatments reach patients. In December 2011, The National Center for Advancing Translational Science (NCATS) was established within the NIH to "transform the translational science process so that new treatments and cures for disease can be delivered to patients faster." The Clinical and Translational Science Awards, established in 2006 and now funded by NCATS, supports 60 centers across the country that provide "academic homes for translational sciences and supporting research resources needed by local and national research communities." According to an article published in 2007 in Science Career Magazine, in 2007 to 2013 the European Commission targeted a majority of its €6 billion budget for health research to further translational medicine.

University of Würzburg started a Master programme in Translational Medicine in 2018. It is aimed at medical students in the third or fourth year pursuing a career as a Clinician Scientist.

Suranaree University of Technology is the second University in Thailand and in Southeast Asia that has a Master and PhD programme in Translational Medicine (MSc 2018 and PhD 2019). MSc and PhD programmes are conducted by Institute of Medicine that contributed by phicians and PhD staffs which are focused in related field of benchside, bedside and community mainly parasites, Bacteria, cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international curriculum that supported by research centers in the university such as Parasitic Disease Research Center (PDRC), Helicobacter pylori and Gastric Cancer Researc Unit, Center of Excellent for Biomedical Engineering, Department of Research Affiare, Institute of Medicine, and Suranaree University of Technology Hospital. These programme will be faciltate students synthesize, analyses and integrate the basic medical science and clinical science for their professional work related to translational medicine. In addition, students will be understand the research process, innovation, and collaboration with multidisciplinary teams for solving health problems.

University of Würzburg started a Master programme in Translational Medicine in 2018. It is aimed at medical students in the third or fourth year pursuing a career as a Clinician Scientist.

Translational medicine is a rapidly growing discipline in biomedical research and aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. Within public health, translational medicine is focused on ensuring that proven strategies for disease treatment and prevention are actually implemented within the community. One prevalent description of translational medicine, first introduced by the Institute of Medicine's Clinical Research Roundtable, highlights two roadblocks (i.e., distinct areas in need of improvement): the first translational block (T1) prevents basic research findings from being tested in a clinical setting; the second translational block (T2) prevents proven interventions from becoming standard practice.

University of Würzburg started a Master programme in Translational Medicine in 2018. It is aimed at medical students in the third or fourth year pursuing a career as a Clinician Scientist.

St. George's University of London offers a 1-year Translational Medicine master's programme since 2018, including pathways leading to a Master of Research (MRes), Master of Science (MSc), Postgraduate Certificate (PGCert) or Postgraduate Diploma (PGDip). Both master's degrees include a research component that makes up 33% of the MSc pathway and 58% of the MRes pathway. Taught modules are designed to cover major areas of modern translational science including drug development, genomics and development of skills related to research and data analysis.

University of Würzburg started a Master programme in Translational Medicine in 2018. It is aimed at medical students in the third or fourth year pursuing a career as a Clinician Scientist.

Academy of Translational Medicine Professionals (ATMP) is working to advance the ongoing knowledge and skills for clinicians and scientific professionals at all levels. Academy’s high quality, standard and ethical training and educational programs ensure that all clinical and scientific professionals achieve excellence in their respective fields. Programs are accredited by the European Society for Translational Medicine (EUSTM).

St. George's University of London offers a 1-year Translational Medicine master's programme since 2018, including pathways leading to a Master of Research (MRes), Master of Science (MSc), Postgraduate Certificate (PGCert) or Postgraduate Diploma (PGDip). Both master's degrees include a research component that makes up 33% of the MSc pathway and 58% of the MRes pathway. Taught modules are designed to cover major areas of modern translational science including drug development, genomics and development of skills related to research and data analysis.

The University of Edinburgh has been running an MSc in Translational Medicine program since 2007. It is a 3-year online distance learning programme aimed at the working health professional.

St. George's University of London offers a 1-year Translational Medicine master's programme since 2018, including pathways leading to a Master of Research (MRes), Master of Science (MSc), Postgraduate Certificate (PGCert) or Postgraduate Diploma (PGDip). Both master's degrees include a research component that makes up 33% of the MSc pathway and 58% of the MRes pathway. Taught modules are designed to cover major areas of modern translational science including drug development, genomics and development of skills related to research and data analysis.

In recent years, a number of educational programs have emerged to provide professional training in the skills necessary for successfully translating research into improved clinical outcomes. These programs go by various names (including Master of Translational Medicine and Master of Science in Bioinnovation). Many such programs emerge from bioengineering departments, often in collaboration with clinical departments.

St. George's University of London offers a 1-year Translational Medicine master's programme since 2018, including pathways leading to a Master of Research (MRes), Master of Science (MSc), Postgraduate Certificate (PGCert) or Postgraduate Diploma (PGDip). Both master's degrees include a research component that makes up 33% of the MSc pathway and 58% of the MRes pathway. Taught modules are designed to cover major areas of modern translational science including drug development, genomics and development of skills related to research and data analysis.

The University of Manchester, Newcastle University and Queen's University Belfast also offer research-focussed Masters of Research (MRes) courses in Translational Medicine.

St. George's University of London offers a 1-year Translational Medicine master's programme since 2018, including pathways leading to a Master of Research (MRes), Master of Science (MSc), Postgraduate Certificate (PGCert) or Postgraduate Diploma (PGDip). Both master's degrees include a research component that makes up 33% of the MSc pathway and 58% of the MRes pathway. Taught modules are designed to cover major areas of modern translational science including drug development, genomics and development of skills related to research and data analysis.

In recent years, a number of educational programs have emerged to provide professional training in the skills necessary for successfully translating research into improved clinical outcomes. These programs go by various names (including Master of Translational Medicine and Master of Science in Bioinnovation). Many such programs emerge from bioengineering departments, often in collaboration with clinical departments.

St. George's University of London offers a 1-year Translational Medicine master's programme since 2018, including pathways leading to a Master of Research (MRes), Master of Science (MSc), Postgraduate Certificate (PGCert) or Postgraduate Diploma (PGDip). Both master's degrees include a research component that makes up 33% of the MSc pathway and 58% of the MRes pathway. Taught modules are designed to cover major areas of modern translational science including drug development, genomics and development of skills related to research and data analysis.

A master's degree programme in translational medicine was started at the University of Helsinki in 2010.

St. George's University of London offers a 1-year Translational Medicine master's programme since 2018, including pathways leading to a Master of Research (MRes), Master of Science (MSc), Postgraduate Certificate (PGCert) or Postgraduate Diploma (PGDip). Both master's degrees include a research component that makes up 33% of the MSc pathway and 58% of the MRes pathway. Taught modules are designed to cover major areas of modern translational science including drug development, genomics and development of skills related to research and data analysis.

In recent years, a number of educational programs have emerged to provide professional training in the skills necessary for successfully translating research into improved clinical outcomes. These programs go by various names (including Master of Translational Medicine and Master of Science in Bioinnovation). Many such programs emerge from bioengineering departments, often in collaboration with clinical departments.

Academy of Translational Medicine Professionals (ATMP) offers a regular professional certification course 'Understanding Translational Medicine Tools and Techniques"

University of Bern is offering a Master of Advanced Studies (MAS), Diplomas of Advanced Studies (DAS) and Certificates of Advanced Studies (CAS) in Translational Medicine and Biomedical Entrepreneurship through sitem-insel School in Bern, Switzerland.

Academy of Translational Medicine Professionals (ATMP) offers a regular professional certification course 'Understanding Translational Medicine Tools and Techniques"

The National Institutes of Health (NIH) has made a major push to fund translational medicine, especially within biomedical research, with a focus on cross-functional collaborations (e.g., between researchers and clinicians); leveraging new technology and data analysis tools; and increasing the speed at which new treatments reach patients. In December 2011, The National Center for Advancing Translational Science (NCATS) was established within the NIH to "transform the translational science process so that new treatments and cures for disease can be delivered to patients faster." The Clinical and Translational Science Awards, established in 2006 and now funded by NCATS, supports 60 centers across the country that provide "academic homes for translational sciences and supporting research resources needed by local and national research communities." According to an article published in 2007 in Science Career Magazine, in 2007 to 2013 the European Commission targeted a majority of its €6 billion budget for health research to further translational medicine.

James Lind Institute has been conducting a Postgraduate Diploma in Translational Medicine since early 2013. The program has been supported by the Universiti Sains Malaysia.

University of Bern is offering a Master of Advanced Studies (MAS), Diplomas of Advanced Studies (DAS) and Certificates of Advanced Studies (CAS) in Translational Medicine and Biomedical Entrepreneurship through sitem-insel School in Bern, Switzerland.

James Lind Institute has been conducting a Postgraduate Diploma in Translational Medicine since early 2013. The program has been supported by the Universiti Sains Malaysia.

Translational medicine is a rapidly growing discipline in biomedical research and aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. Within public health, translational medicine is focused on ensuring that proven strategies for disease treatment and prevention are actually implemented within the community. One prevalent description of translational medicine, first introduced by the Institute of Medicine's Clinical Research Roundtable, highlights two roadblocks (i.e., distinct areas in need of improvement): the first translational block (T1) prevents basic research findings from being tested in a clinical setting; the second translational block (T2) prevents proven interventions from becoming standard practice.

The University of Southern California (USC) School of Pharmacy offers a course in Translational Medicine.

James Lind Institute has been conducting a Postgraduate Diploma in Translational Medicine since early 2013. The program has been supported by the Universiti Sains Malaysia.

The University of Southern California (USC) School of Pharmacy offers a course in Translational Medicine.

The society facilitates cooperation and interaction among clinicians, scientists, academia, industry, governments, funding and regulatory agencies, investors and policy makers in order to develop and deliver high quality translational medicine programs and initiatives with overall aim to enhance the healthcare of global population. The society׳s goal is to enhance research and development of novel and affordable diagnostic tools and treatments for the clinical disorders affecting global population.

University of Bern is offering a Master of Advanced Studies (MAS), Diplomas of Advanced Studies (DAS) and Certificates of Advanced Studies (CAS) in Translational Medicine and Biomedical Entrepreneurship through sitem-insel School in Bern, Switzerland.

James Lind Institute has been conducting a Postgraduate Diploma in Translational Medicine since early 2013. The program has been supported by the Universiti Sains Malaysia.

University of Bern is offering a Master of Advanced Studies (MAS), Diplomas of Advanced Studies (DAS) and Certificates of Advanced Studies (CAS) in Translational Medicine and Biomedical Entrepreneurship through sitem-insel School in Bern, Switzerland.

The National Institutes of Health (NIH) has made a major push to fund translational medicine, especially within biomedical research, with a focus on cross-functional collaborations (e.g., between researchers and clinicians); leveraging new technology and data analysis tools; and increasing the speed at which new treatments reach patients. In December 2011, The National Center for Advancing Translational Science (NCATS) was established within the NIH to "transform the translational science process so that new treatments and cures for disease can be delivered to patients faster." The Clinical and Translational Science Awards, established in 2006 and now funded by NCATS, supports 60 centers across the country that provide "academic homes for translational sciences and supporting research resources needed by local and national research communities." According to an article published in 2007 in Science Career Magazine, in 2007 to 2013 the European Commission targeted a majority of its €6 billion budget for health research to further translational medicine.

The European Society for Translational Medicine (EUSTM) is a global non-profit and neutral healthcare organization whose principal objective is to enhance world-wide healthcare by using translational medicine approaches, resources and expertise.

In response to the COVID-19 coronavirus pandemic, the European Society for Translational Medicine (EUSTM) has announced a global virtual congress on COVID-19 (EUSTM-2020). The Virtual Congress will focus on the key principles of Translational Medicine: Bench side, Bed side and Public Health. The congress aims to address current challenges, highlight novel solutions and identify critical hurdles as they apply to COVID-19.

The European Society for Translational Medicine (EUSTM) is a global non-profit and neutral healthcare organization whose principal objective is to enhance world-wide healthcare by using translational medicine approaches, resources and expertise.

Translational medicine:2733891

The society facilitates cooperation and interaction among clinicians, scientists, academia, industry, governments, funding and regulatory agencies, investors and policy makers in order to develop and deliver high quality translational medicine programs and initiatives with overall aim to enhance the healthcare of global population. The society׳s goal is to enhance research and development of novel and affordable diagnostic tools and treatments for the clinical disorders affecting global population.

The society provides an annual platform in the form of global congresses where global key opinion leaders, scientists from bench side, public health professionals, clinicians from bedside and industry professionals gather and take part in the panel discussions and scientific sessions on latest updates and developments in translational medicine field including biomarkers, omics sciences, cellular and molecular biology, data mining & management, precision medicine & companion diagnostics, disease modelling, vaccines and community healthcare.

The society facilitates cooperation and interaction among clinicians, scientists, academia, industry, governments, funding and regulatory agencies, investors and policy makers in order to develop and deliver high quality translational medicine programs and initiatives with overall aim to enhance the healthcare of global population. The society׳s goal is to enhance research and development of novel and affordable diagnostic tools and treatments for the clinical disorders affecting global population.

Academy of Translational Medicine Professionals (ATMP) offers a regular professional certification course 'Understanding Translational Medicine Tools and Techniques"

The society provides an annual platform in the form of global congresses where global key opinion leaders, scientists from bench side, public health professionals, clinicians from bedside and industry professionals gather and take part in the panel discussions and scientific sessions on latest updates and developments in translational medicine field including biomarkers, omics sciences, cellular and molecular biology, data mining & management, precision medicine & companion diagnostics, disease modelling, vaccines and community healthcare.

In response to the COVID-19 coronavirus pandemic, the European Society for Translational Medicine (EUSTM) has announced a global virtual congress on COVID-19 (EUSTM-2020). The Virtual Congress will focus on the key principles of Translational Medicine: Bench side, Bed side and Public Health. The congress aims to address current challenges, highlight novel solutions and identify critical hurdles as they apply to COVID-19.

The society provides an annual platform in the form of global congresses where global key opinion leaders, scientists from bench side, public health professionals, clinicians from bedside and industry professionals gather and take part in the panel discussions and scientific sessions on latest updates and developments in translational medicine field including biomarkers, omics sciences, cellular and molecular biology, data mining & management, precision medicine & companion diagnostics, disease modelling, vaccines and community healthcare.

Suranaree University of Technology is the second University in Thailand and in Southeast Asia that has a Master and PhD programme in Translational Medicine (MSc 2018 and PhD 2019). MSc and PhD programmes are conducted by Institute of Medicine that contributed by phicians and PhD staffs which are focused in related field of benchside, bedside and community mainly parasites, Bacteria, cholangiocarcinoma, gastric cance, musculoskeletal diseases, etc. Translational Medicine programme is an international curriculum that supported by research centers in the university such as Parasitic Disease Research Center (PDRC), Helicobacter pylori and Gastric Cancer Researc Unit, Center of Excellent for Biomedical Engineering, Department of Research Affiare, Institute of Medicine, and Suranaree University of Technology Hospital. These programme will be faciltate students synthesize, analyses and integrate the basic medical science and clinical science for their professional work related to translational medicine. In addition, students will be understand the research process, innovation, and collaboration with multidisciplinary teams for solving health problems.

In response to the COVID-19 coronavirus pandemic, the European Society for Translational Medicine (EUSTM) has announced a global virtual congress on COVID-19 (EUSTM-2020). The Virtual Congress will focus on the key principles of Translational Medicine: Bench side, Bed side and Public Health. The congress aims to address current challenges, highlight novel solutions and identify critical hurdles as they apply to COVID-19.

The society provides an annual platform in the form of global congresses where global key opinion leaders, scientists from bench side, public health professionals, clinicians from bedside and industry professionals gather and take part in the panel discussions and scientific sessions on latest updates and developments in translational medicine field including biomarkers, omics sciences, cellular and molecular biology, data mining & management, precision medicine & companion diagnostics, disease modelling, vaccines and community healthcare.

In response to the COVID-19 coronavirus pandemic, the European Society for Translational Medicine (EUSTM) has announced a global virtual congress on COVID-19 (EUSTM-2020). The Virtual Congress will focus on the key principles of Translational Medicine: Bench side, Bed side and Public Health. The congress aims to address current challenges, highlight novel solutions and identify critical hurdles as they apply to COVID-19.

Academy of Translational Medicine Professionals (ATMP) is working to advance the ongoing knowledge and skills for clinicians and scientific professionals at all levels. Academy’s high quality, standard and ethical training and educational programs ensure that all clinical and scientific professionals achieve excellence in their respective fields. Programs are accredited by the European Society for Translational Medicine (EUSTM).

DFI:2984191

DFI was founded by Y.C Lu on July 14, 1981, developing and selling electronics components and add-on cards in the beginning. However, DFI switched to the production of motherboards after searching for potential markets and deciding to focus on the strengths of DFI. Targeting the new growing market in motherboard products, DFI announced the Patent License Agreement with Intel Corporation to build partnership with Intel in 1990 and has been developing and manufacturing motherboard products since 1992. With continuous dedication, DFI quickly gained a reputation in Asia-Pacific region after five years and was awarded Top 10 Motherboard Manufacturer in CRN Magazine from the year 1997 to 1999. Starting from 1998, DFI began to follow the strategies of Intel by releasing Intel 440BX series motherboards, 810 motherboards, and 810e motherboards to worldwide markets. Since its growing advances in manufacturing motherboards, DFI was awarded the Intel Global Demo Board manufacturer award in 1998 and 1999 respectively.

DFI:2984191

In May 2011, DFI's process-on-order factory in China was transformed into Sole proprietorship, which was capitalized with US$2.5 million. To expand its industrial computer business, DFI established a system engineering department to fulfill highly dedicated researches and design developments for the future. In 2012, DFI launched a product line based on Intel Atom® Processor D2550/N2800 (code name: Cedar Trail), including Mini-ITX form factor motherboard CD101-N, COM Express Compact CD905-B, 3.5" SBC motherboard CD951, and embedded system DS910-CD. On June 4, 2014, DFI established Yan Ying Hao Trading Co. Ltd.in ShenZhen, and started to develop business in the China region. To accommodate increasing growth and expansion, DFI relocated its corporate headquarter to Farglory U-Town building in New Taipei City. In 2016, DFI has released Qualcomm-based motherboard and medical industrial computer that dedicate itself to various fields and expand its business with different platforms. DFI has joined Qisda/BenQ Group. In the second half year of 2018, DFI has added the new SMT line to the factory to scale up its facilities and production capability.

DFI:2984191

DFI is a Taiwanese industrial computer company with headquarters in Taipei. It designs, develops, manufactures, and sells industrial motherboard, industrial PCs, System-on-Module, industrial displays, and ODM/OEM services.

DFI:2984191

In 1981, Y.C Lu founded DFI Electronics Components Inc. in Taipei, Taiwan; mainly supplying and exporting electronics components with $1 million in capital. During the first year, DFI earned a revenue of $30 million. In 1984, DFI established facility in Taipei and began manufacturing and selling computers and peripherals. When the capital increased up to $10 million, the Sales (Revenue) Growth Rate of DFI also increased to 300% and DFI successfully expanded its operations to the American regions as well as earning nearly $1 billion in revenues. In 1987, with the capital of $30 million, DFI started to establish facility in Hsi-Chih City, Taiwan. At the same time, DFI planned to stretch its product line into the European markets, starting with Germany and England. As of 1988, the facility relocated to Hsi-Chih City, which was the major facility of DFI. With the expansion of production line and the addition of Automatic Test Equipment (ATE), DFI not only upgraded the quality of products, but also released a handheld scanner. As of 1989, DFI added Computer Aided Design System (CAD) to its facility to manufacture more products like computer mouse, handheld scanner, personal computer, and add-on card, etc. In 1990, DFI announced its Patent License Agreement with Intel Corporation and became the first company with an assembly production line in America to enable technical support service in cooperation with Intel. DFI's capital increased to $196 million and expanded its facility to 1,900 square feet in 1991.

DFI is a Taiwanese industrial computer company with headquarters in Taipei. It designs, develops, manufactures, and sells industrial motherboard, industrial PCs, System-on-Module, industrial displays, and ODM/OEM services.

Since DFI planned to focus on developing embedded system products, not only did they stop developing Consumer Product Line, but also started establishing embedded system developments and designs in 2011 to expand its industrial computer business.

DFI is a Taiwanese industrial computer company with headquarters in Taipei. It designs, develops, manufactures, and sells industrial motherboard, industrial PCs, System-on-Module, industrial displays, and ODM/OEM services.

As of 1992, DFI introduced ICT and SMT devices into its facility to increase the manufacturing quality and efficiency. In 1993, DFI continually expanded the facility, which was located in Hsi-Chih City and was 2,300 square feet. DFI's business office and Research and Development Department moved to the facility and introduced Green PC with energy-efficiency design into the facility. As of 1994, DFI researched and developed CD-ROM, officially entered into multimedia system market. The revenue of the notebook increased to over $100 million and the overall revenue of 1994 increased by 25%, over $2 billion. As of 1996, DFI transformed the CD-ROM facility into an assembly system facility, designing and manufacturing the world's first 75MHZ system bus motherboard, which supported the CYRIX PR 200+CPU. In the meantime, DFI began establishing the third SMT assembly and adopted Siemens SIPLACE80S-15 high speed CNC machine to increase the production of motherboards to 40,000 pcs per month, as well as increasing the self-production to 120, 000 per month. After manufacturing 586 motherboards that supported dual CPU, DFI was dominant in the motherboard market and targeted developing countries, accommodating to Philips Asian marketing system. As of 1997, DFI expanded the facility in Hsi-Chih City for the third time, totaling the area to 2, 800 square feet. DFI also expanded 2 surface mount technology (SMT) high speed CNC machines to upgrade the production of motherboards to 180, 000 pcs per month. Devoted to developing Philips and Lemel assembly OEM business, DFI manufactured 10, 000 systems every month. At the same time, DFI established a third OEM assembly facility in Dongguan city, China and built a European branch office in Bremen, Germany in order to advance the quality of services in European regions. Being engaged in the server market, DFI got started in designing and developing motherboards that support SCSI onboard and Dual Pentium CPU in 1997. From the year of 1997 to 1999, DFI was awarded the Top 10 Motherboard Manufacturer in CRN (Computer Reseller New) Magazine, which had already gained attention by the worldwide market due to DFI's motherboards’ design and development. In April, 1998, DFI was preparing to apply for becoming a listed company at Taipei Exchange (TPEx) and TWSE. In the same year, DFI released Intel 440BX series motherboard, which was in line with Intel. The 810 motherboard of DFI was awarded the Demo Board amongst Intel Asia-Pacific region. In February, 1999, P5BV3＋motherboards was awarded the high performance Socket7 motherboard in Computer World Magazine in China. In early May of the same year, DFI launched 810 motherboard to the market, following the release of Intel and had already gone into mass production worldwide. The 810e motherboard was re-awarded Intel Global Demo Board and was launched to the market in September, 1999. DFI went public and launched its initial public offering (IPO) on 15, January, 2000. During the same year, DFI founded Diamond Flower H.T. Group (BVI) Inc.

DFI is a Taiwanese industrial computer company with headquarters in Taipei. It designs, develops, manufactures, and sells industrial motherboard, industrial PCs, System-on-Module, industrial displays, and ODM/OEM services.

DFI was founded by Y.C Lu on July 14, 1981, developing and selling electronics components and add-on cards in the beginning. However, DFI switched to the production of motherboards after searching for potential markets and deciding to focus on the strengths of DFI. Targeting the new growing market in motherboard products, DFI announced the Patent License Agreement with Intel Corporation to build partnership with Intel in 1990 and has been developing and manufacturing motherboard products since 1992. With continuous dedication, DFI quickly gained a reputation in Asia-Pacific region after five years and was awarded Top 10 Motherboard Manufacturer in CRN Magazine from the year 1997 to 1999. Starting from 1998, DFI began to follow the strategies of Intel by releasing Intel 440BX series motherboards, 810 motherboards, and 810e motherboards to worldwide markets. Since its growing advances in manufacturing motherboards, DFI was awarded the Intel Global Demo Board manufacturer award in 1998 and 1999 respectively.

DFI is a Taiwanese industrial computer company with headquarters in Taipei. It designs, develops, manufactures, and sells industrial motherboard, industrial PCs, System-on-Module, industrial displays, and ODM/OEM services.

As of 2012, DFI stopped consumer product line and no longer produced high-end gamer boards such as the LanParty series for end users

DFI was founded by Y.C Lu on July 14, 1981, developing and selling electronics components and add-on cards in the beginning. However, DFI switched to the production of motherboards after searching for potential markets and deciding to focus on the strengths of DFI. Targeting the new growing market in motherboard products, DFI announced the Patent License Agreement with Intel Corporation to build partnership with Intel in 1990 and has been developing and manufacturing motherboard products since 1992. With continuous dedication, DFI quickly gained a reputation in Asia-Pacific region after five years and was awarded Top 10 Motherboard Manufacturer in CRN Magazine from the year 1997 to 1999. Starting from 1998, DFI began to follow the strategies of Intel by releasing Intel 440BX series motherboards, 810 motherboards, and 810e motherboards to worldwide markets. Since its growing advances in manufacturing motherboards, DFI was awarded the Intel Global Demo Board manufacturer award in 1998 and 1999 respectively.

Catering to the growing market of high-end motherboards, DFI developed advanced overclocking motherboards, the LanParty series, which has proven to be a valuable segment for small powerful computers that meet the requirements of end users in the 2000s. DFI introduced the junior lineup (“JR”) with two products, p45 and 790gx, in the beginning, which has since been extended with Nvidia and X58 chipsets. There are other LanParty series like LT, DK(Dark), and Lanparty UT.

DFI was founded by Y.C Lu on July 14, 1981, developing and selling electronics components and add-on cards in the beginning. However, DFI switched to the production of motherboards after searching for potential markets and deciding to focus on the strengths of DFI. Targeting the new growing market in motherboard products, DFI announced the Patent License Agreement with Intel Corporation to build partnership with Intel in 1990 and has been developing and manufacturing motherboard products since 1992. With continuous dedication, DFI quickly gained a reputation in Asia-Pacific region after five years and was awarded Top 10 Motherboard Manufacturer in CRN Magazine from the year 1997 to 1999. Starting from 1998, DFI began to follow the strategies of Intel by releasing Intel 440BX series motherboards, 810 motherboards, and 810e motherboards to worldwide markets. Since its growing advances in manufacturing motherboards, DFI was awarded the Intel Global Demo Board manufacturer award in 1998 and 1999 respectively.

DFI is also manufacturing motherboards for various industrial purposes. DFI-ACP is a Wintel based platform provider for non-PC business, products range from board level, open frame, add-on boards to barebone systems.

DFI was founded by Y.C Lu on July 14, 1981, developing and selling electronics components and add-on cards in the beginning. However, DFI switched to the production of motherboards after searching for potential markets and deciding to focus on the strengths of DFI. Targeting the new growing market in motherboard products, DFI announced the Patent License Agreement with Intel Corporation to build partnership with Intel in 1990 and has been developing and manufacturing motherboard products since 1992. With continuous dedication, DFI quickly gained a reputation in Asia-Pacific region after five years and was awarded Top 10 Motherboard Manufacturer in CRN Magazine from the year 1997 to 1999. Starting from 1998, DFI began to follow the strategies of Intel by releasing Intel 440BX series motherboards, 810 motherboards, and 810e motherboards to worldwide markets. Since its growing advances in manufacturing motherboards, DFI was awarded the Intel Global Demo Board manufacturer award in 1998 and 1999 respectively.

With blossoming business in the market, DFI went public and launched its initial public offering (IPO) on January 15, 2000. DFI has already gained a reputation from its motherboard products and hot-selling lineup, LanParty, at that time. And aside from developing LanParty consumer products, DFI started to develop ACP (Application Control Platform) businesses, mainly targeted at vertical applications in slot machine, POS, security system, and so on since 2002. In 2005, DFI gained over 50% revenues from this new business. With this successful transformation, industrial computer became the primary business of DFI. As of 2003, DFI's renowned overclocked gamer motherboard, LANPARTY NFII ULTRA, was awarded the Chief Editor Choice Award in PC Magazine and the Best Creativity Award in Tom's Hardware Guide.

DFI was founded by Y.C Lu on July 14, 1981, developing and selling electronics components and add-on cards in the beginning. However, DFI switched to the production of motherboards after searching for potential markets and deciding to focus on the strengths of DFI. Targeting the new growing market in motherboard products, DFI announced the Patent License Agreement with Intel Corporation to build partnership with Intel in 1990 and has been developing and manufacturing motherboard products since 1992. With continuous dedication, DFI quickly gained a reputation in Asia-Pacific region after five years and was awarded Top 10 Motherboard Manufacturer in CRN Magazine from the year 1997 to 1999. Starting from 1998, DFI began to follow the strategies of Intel by releasing Intel 440BX series motherboards, 810 motherboards, and 810e motherboards to worldwide markets. Since its growing advances in manufacturing motherboards, DFI was awarded the Intel Global Demo Board manufacturer award in 1998 and 1999 respectively.

In May 2011, DFI's process-on-order factory in China was transformed into Sole proprietorship, which was capitalized with US$2.5 million. To expand its industrial computer business, DFI established a system engineering department to fulfill highly dedicated researches and design developments for the future. In 2012, DFI launched a product line based on Intel Atom® Processor D2550/N2800 (code name: Cedar Trail), including Mini-ITX form factor motherboard CD101-N, COM Express Compact CD905-B, 3.5" SBC motherboard CD951, and embedded system DS910-CD. On June 4, 2014, DFI established Yan Ying Hao Trading Co. Ltd.in ShenZhen, and started to develop business in the China region. To accommodate increasing growth and expansion, DFI relocated its corporate headquarter to Farglory U-Town building in New Taipei City. In 2016, DFI has released Qualcomm-based motherboard and medical industrial computer that dedicate itself to various fields and expand its business with different platforms. DFI has joined Qisda/BenQ Group. In the second half year of 2018, DFI has added the new SMT line to the factory to scale up its facilities and production capability.

Catering to the growing market of high-end motherboards, DFI developed advanced overclocking motherboards, the LanParty series, which has proven to be a valuable segment for small powerful computers that meet the requirements of end users in the 2000s. DFI introduced the junior lineup (“JR”) with two products, p45 and 790gx, in the beginning, which has since been extended with Nvidia and X58 chipsets. There are other LanParty series like LT, DK(Dark), and Lanparty UT.

DFI:2984191

Catering to the growing market of high-end motherboards, DFI developed advanced overclocking motherboards, the LanParty series, which has proven to be a valuable segment for small powerful computers that meet the requirements of end users in the 2000s. DFI introduced the junior lineup (“JR”) with two products, p45 and 790gx, in the beginning, which has since been extended with Nvidia and X58 chipsets. There are other LanParty series like LT, DK(Dark), and Lanparty UT.

DFI is also manufacturing motherboards for various industrial purposes. DFI-ACP is a Wintel based platform provider for non-PC business, products range from board level, open frame, add-on boards to barebone systems.

Catering to the growing market of high-end motherboards, DFI developed advanced overclocking motherboards, the LanParty series, which has proven to be a valuable segment for small powerful computers that meet the requirements of end users in the 2000s. DFI introduced the junior lineup (“JR”) with two products, p45 and 790gx, in the beginning, which has since been extended with Nvidia and X58 chipsets. There are other LanParty series like LT, DK(Dark), and Lanparty UT.

DFI was founded by Y.C Lu on July 14, 1981, developing and selling electronics components and add-on cards in the beginning. However, DFI switched to the production of motherboards after searching for potential markets and deciding to focus on the strengths of DFI. Targeting the new growing market in motherboard products, DFI announced the Patent License Agreement with Intel Corporation to build partnership with Intel in 1990 and has been developing and manufacturing motherboard products since 1992. With continuous dedication, DFI quickly gained a reputation in Asia-Pacific region after five years and was awarded Top 10 Motherboard Manufacturer in CRN Magazine from the year 1997 to 1999. Starting from 1998, DFI began to follow the strategies of Intel by releasing Intel 440BX series motherboards, 810 motherboards, and 810e motherboards to worldwide markets. Since its growing advances in manufacturing motherboards, DFI was awarded the Intel Global Demo Board manufacturer award in 1998 and 1999 respectively.

Catering to the growing market of high-end motherboards, DFI developed advanced overclocking motherboards, the LanParty series, which has proven to be a valuable segment for small powerful computers that meet the requirements of end users in the 2000s. DFI introduced the junior lineup (“JR”) with two products, p45 and 790gx, in the beginning, which has since been extended with Nvidia and X58 chipsets. There are other LanParty series like LT, DK(Dark), and Lanparty UT.

In May 2011, DFI's process-on-order factory in China was transformed into Sole proprietorship, which was capitalized with US$2.5 million. To expand its industrial computer business, DFI established a system engineering department to fulfill highly dedicated researches and design developments for the future. In 2012, DFI launched a product line based on Intel Atom® Processor D2550/N2800 (code name: Cedar Trail), including Mini-ITX form factor motherboard CD101-N, COM Express Compact CD905-B, 3.5" SBC motherboard CD951, and embedded system DS910-CD. On June 4, 2014, DFI established Yan Ying Hao Trading Co. Ltd.in ShenZhen, and started to develop business in the China region. To accommodate increasing growth and expansion, DFI relocated its corporate headquarter to Farglory U-Town building in New Taipei City. In 2016, DFI has released Qualcomm-based motherboard and medical industrial computer that dedicate itself to various fields and expand its business with different platforms. DFI has joined Qisda/BenQ Group. In the second half year of 2018, DFI has added the new SMT line to the factory to scale up its facilities and production capability.

With blossoming business in the market, DFI went public and launched its initial public offering (IPO) on January 15, 2000. DFI has already gained a reputation from its motherboard products and hot-selling lineup, LanParty, at that time. And aside from developing LanParty consumer products, DFI started to develop ACP (Application Control Platform) businesses, mainly targeted at vertical applications in slot machine, POS, security system, and so on since 2002. In 2005, DFI gained over 50% revenues from this new business. With this successful transformation, industrial computer became the primary business of DFI. As of 2003, DFI's renowned overclocked gamer motherboard, LANPARTY NFII ULTRA, was awarded the Chief Editor Choice Award in PC Magazine and the Best Creativity Award in Tom's Hardware Guide.

Since DFI planned to focus on developing embedded system products, not only did they stop developing Consumer Product Line, but also started establishing embedded system developments and designs in 2011 to expand its industrial computer business.

With blossoming business in the market, DFI went public and launched its initial public offering (IPO) on January 15, 2000. DFI has already gained a reputation from its motherboard products and hot-selling lineup, LanParty, at that time. And aside from developing LanParty consumer products, DFI started to develop ACP (Application Control Platform) businesses, mainly targeted at vertical applications in slot machine, POS, security system, and so on since 2002. In 2005, DFI gained over 50% revenues from this new business. With this successful transformation, industrial computer became the primary business of DFI. As of 2003, DFI's renowned overclocked gamer motherboard, LANPARTY NFII ULTRA, was awarded the Chief Editor Choice Award in PC Magazine and the Best Creativity Award in Tom's Hardware Guide.

DFI is also manufacturing motherboards for various industrial purposes. DFI-ACP is a Wintel based platform provider for non-PC business, products range from board level, open frame, add-on boards to barebone systems.

With blossoming business in the market, DFI went public and launched its initial public offering (IPO) on January 15, 2000. DFI has already gained a reputation from its motherboard products and hot-selling lineup, LanParty, at that time. And aside from developing LanParty consumer products, DFI started to develop ACP (Application Control Platform) businesses, mainly targeted at vertical applications in slot machine, POS, security system, and so on since 2002. In 2005, DFI gained over 50% revenues from this new business. With this successful transformation, industrial computer became the primary business of DFI. As of 2003, DFI's renowned overclocked gamer motherboard, LANPARTY NFII ULTRA, was awarded the Chief Editor Choice Award in PC Magazine and the Best Creativity Award in Tom's Hardware Guide.

DFI:2984191

With blossoming business in the market, DFI went public and launched its initial public offering (IPO) on January 15, 2000. DFI has already gained a reputation from its motherboard products and hot-selling lineup, LanParty, at that time. And aside from developing LanParty consumer products, DFI started to develop ACP (Application Control Platform) businesses, mainly targeted at vertical applications in slot machine, POS, security system, and so on since 2002. In 2005, DFI gained over 50% revenues from this new business. With this successful transformation, industrial computer became the primary business of DFI. As of 2003, DFI's renowned overclocked gamer motherboard, LANPARTY NFII ULTRA, was awarded the Chief Editor Choice Award in PC Magazine and the Best Creativity Award in Tom's Hardware Guide.

Intel 960 Series Chipsets (code name: Crestline), including different form factors consisting of SR100-L20C Mini-ITX motherboard and SR330-L microATX motherboard. In the same year, DFI also launched a product line based on Intel 945P Chipsets (code name: Lakeport), covering different form factors like G7L331-B microATX motherboard and LT600-D ATX motherboard. As of 2007, DFI's capital increased to NTD1.14 billion as well as a 65.77% equity of DFI-ITOX with acquisition cost of NTD 234 million. To guarantee exceptional quality and reliability of products under rigorous quality standards, DFI's products were approved by QC080000, WASO14001, and Green Partner certifications in 2007. DFI launched a product line based on Intel G41 Chipsets (code name: Eagle Lake), inclusive of EL109-N Mini-ITX motherboard, EL339-B microATX motherboard, and EL620-C ATX motherboard, as well as HNVR320-EL embedded system. In 2007, DFI also released a product line based on Intel Q35 Chipsets (code name: Bearlake), ranging from BL100-NE/PE Mini-ITX motherboard, to BL330-B microATX motherboard, to BL631-D ATX motherboard, As of 2008, DFI's capital increased to NTD 1.19 billion, acquiring 100% equity of YAN TONG TECHNOLOGYLTD with acquisition cost of NTD 187.26 million, as well as increasing the capital to DFI-Japan to JPY 280 million. In 2008, DFI released a product line based on Intel GM45 Chipsets (code name: Cantiga), ranging from CA900-B COM Express Basic, to small form factor CA230-BF Mini-DTX board, to CA101-D Mini-ITX motherboard, to CA331-P microATX motherboard. Furthermore, DFI launched a product series based on Intel Atom Processor Z500 series (code name: Silverthorne), offering from ML905-B11C/B16C COM Express, to small form factor ML936-B11C/B16C board, to CS910-ML embedded system. In the same year, DFI also kicked off a full range of product series which were based on Intel 945GSE Chipsets (code name: Navy Pier), covering from NP102-N16C Mini-ITX motherboard, to NP905-B16C COM Express Compact, to NP951-B16C small form factor 3.5" SBC, to ES122-NP embedded system. As of 2009, DFI's capital increased to NTD 1.21 billion. And DFI launched a lineup including PT330-DRM microATX motherboard, PT631-IPM ATX motherboard, and HNVR320-PT embedded system based on Intel Core/Intel Pentium Processors (code name: Piketon). In 2010, DFI's capital increased to NTD 1.202 billion. DFI also launched a product line including CP100-NRM Mini-ITX motherboard, CP330-NRM microATX motherboard, CP908-B COM Express Compact, and ST101-CP embedded system based on Intel Core/Intel® Celeron® Processors with Mobile Intel QM57 Chipset (code name: Calpella).

Since DFI planned to focus on developing embedded system products, not only did they stop developing Consumer Product Line, but also started establishing embedded system developments and designs in 2011 to expand its industrial computer business.

DFI:2984191

Since DFI planned to focus on developing embedded system products, not only did they stop developing Consumer Product Line, but also started establishing embedded system developments and designs in 2011 to expand its industrial computer business.

In May 2011, DFI's process-on-order factory in China was transformed into Sole proprietorship, which was capitalized with US$2.5 million. To expand its industrial computer business, DFI established a system engineering department to fulfill highly dedicated researches and design developments for the future. In 2012, DFI launched a product line based on Intel Atom® Processor D2550/N2800 (code name: Cedar Trail), including Mini-ITX form factor motherboard CD101-N, COM Express Compact CD905-B, 3.5" SBC motherboard CD951, and embedded system DS910-CD. On June 4, 2014, DFI established Yan Ying Hao Trading Co. Ltd.in ShenZhen, and started to develop business in the China region. To accommodate increasing growth and expansion, DFI relocated its corporate headquarter to Farglory U-Town building in New Taipei City. In 2016, DFI has released Qualcomm-based motherboard and medical industrial computer that dedicate itself to various fields and expand its business with different platforms. DFI has joined Qisda/BenQ Group. In the second half year of 2018, DFI has added the new SMT line to the factory to scale up its facilities and production capability.

Since DFI planned to focus on developing embedded system products, not only did they stop developing Consumer Product Line, but also started establishing embedded system developments and designs in 2011 to expand its industrial computer business.

Catering to the growing market of high-end motherboards, DFI developed advanced overclocking motherboards, the LanParty series, which has proven to be a valuable segment for small powerful computers that meet the requirements of end users in the 2000s. DFI introduced the junior lineup (“JR”) with two products, p45 and 790gx, in the beginning, which has since been extended with Nvidia and X58 chipsets. There are other LanParty series like LT, DK(Dark), and Lanparty UT.

Since DFI planned to focus on developing embedded system products, not only did they stop developing Consumer Product Line, but also started establishing embedded system developments and designs in 2011 to expand its industrial computer business.

As of 2012, DFI stopped consumer product line and no longer produced high-end gamer boards such as the LanParty series for end users

As of 2006, GE became the vital investor of DFI, benefiting from a large amount of DFI's business as well as acquiring 100% equity of DFI-Japan. With the acquisition cost of NTD 24.55 million, it allowed DFI to completely devote itself to in-depth industrial computer market in Japan. In the following three years, the consolidated revenue growth rate in ACP (Applied Computing Platform) business increased over 51%. DFI then launched a product line based on

DFI also launched system-on-module Qseven, QB700-B + Q7951, which was powered by Intel Atom E600 series processors (code name: Queensbay). In the end of 2010, DFI launched LR100-N18D/S/M Mini-ITX motherboard, LR905-B18D/S/M COM Express, and EC200/210/220/221 embedded system, which were based on

As of 2006, GE became the vital investor of DFI, benefiting from a large amount of DFI's business as well as acquiring 100% equity of DFI-Japan. With the acquisition cost of NTD 24.55 million, it allowed DFI to completely devote itself to in-depth industrial computer market in Japan. In the following three years, the consolidated revenue growth rate in ACP (Applied Computing Platform) business increased over 51%. DFI then launched a product line based on

As of 1992, DFI introduced ICT and SMT devices into its facility to increase the manufacturing quality and efficiency. In 1993, DFI continually expanded the facility, which was located in Hsi-Chih City and was 2,300 square feet. DFI's business office and Research and Development Department moved to the facility and introduced Green PC with energy-efficiency design into the facility. As of 1994, DFI researched and developed CD-ROM, officially entered into multimedia system market. The revenue of the notebook increased to over $100 million and the overall revenue of 1994 increased by 25%, over $2 billion. As of 1996, DFI transformed the CD-ROM facility into an assembly system facility, designing and manufacturing the world's first 75MHZ system bus motherboard, which supported the CYRIX PR 200+CPU. In the meantime, DFI began establishing the third SMT assembly and adopted Siemens SIPLACE80S-15 high speed CNC machine to increase the production of motherboards to 40,000 pcs per month, as well as increasing the self-production to 120, 000 per month. After manufacturing 586 motherboards that supported dual CPU, DFI was dominant in the motherboard market and targeted developing countries, accommodating to Philips Asian marketing system. As of 1997, DFI expanded the facility in Hsi-Chih City for the third time, totaling the area to 2, 800 square feet. DFI also expanded 2 surface mount technology (SMT) high speed CNC machines to upgrade the production of motherboards to 180, 000 pcs per month. Devoted to developing Philips and Lemel assembly OEM business, DFI manufactured 10, 000 systems every month. At the same time, DFI established a third OEM assembly facility in Dongguan city, China and built a European branch office in Bremen, Germany in order to advance the quality of services in European regions. Being engaged in the server market, DFI got started in designing and developing motherboards that support SCSI onboard and Dual Pentium CPU in 1997. From the year of 1997 to 1999, DFI was awarded the Top 10 Motherboard Manufacturer in CRN (Computer Reseller New) Magazine, which had already gained attention by the worldwide market due to DFI's motherboards’ design and development. In April, 1998, DFI was preparing to apply for becoming a listed company at Taipei Exchange (TPEx) and TWSE. In the same year, DFI released Intel 440BX series motherboard, which was in line with Intel. The 810 motherboard of DFI was awarded the Demo Board amongst Intel Asia-Pacific region. In February, 1999, P5BV3＋motherboards was awarded the high performance Socket7 motherboard in Computer World Magazine in China. In early May of the same year, DFI launched 810 motherboard to the market, following the release of Intel and had already gone into mass production worldwide. The 810e motherboard was re-awarded Intel Global Demo Board and was launched to the market in September, 1999. DFI went public and launched its initial public offering (IPO) on 15, January, 2000. During the same year, DFI founded Diamond Flower H.T. Group (BVI) Inc.

Intel 960 Series Chipsets (code name: Crestline), including different form factors consisting of SR100-L20C Mini-ITX motherboard and SR330-L microATX motherboard. In the same year, DFI also launched a product line based on Intel 945P Chipsets (code name: Lakeport), covering different form factors like G7L331-B microATX motherboard and LT600-D ATX motherboard. As of 2007, DFI's capital increased to NTD1.14 billion as well as a 65.77% equity of DFI-ITOX with acquisition cost of NTD 234 million. To guarantee exceptional quality and reliability of products under rigorous quality standards, DFI's products were approved by QC080000, WASO14001, and Green Partner certifications in 2007. DFI launched a product line based on Intel G41 Chipsets (code name: Eagle Lake), inclusive of EL109-N Mini-ITX motherboard, EL339-B microATX motherboard, and EL620-C ATX motherboard, as well as HNVR320-EL embedded system. In 2007, DFI also released a product line based on Intel Q35 Chipsets (code name: Bearlake), ranging from BL100-NE/PE Mini-ITX motherboard, to BL330-B microATX motherboard, to BL631-D ATX motherboard, As of 2008, DFI's capital increased to NTD 1.19 billion, acquiring 100% equity of YAN TONG TECHNOLOGYLTD with acquisition cost of NTD 187.26 million, as well as increasing the capital to DFI-Japan to JPY 280 million. In 2008, DFI released a product line based on Intel GM45 Chipsets (code name: Cantiga), ranging from CA900-B COM Express Basic, to small form factor CA230-BF Mini-DTX board, to CA101-D Mini-ITX motherboard, to CA331-P microATX motherboard. Furthermore, DFI launched a product series based on Intel Atom Processor Z500 series (code name: Silverthorne), offering from ML905-B11C/B16C COM Express, to small form factor ML936-B11C/B16C board, to CS910-ML embedded system. In the same year, DFI also kicked off a full range of product series which were based on Intel 945GSE Chipsets (code name: Navy Pier), covering from NP102-N16C Mini-ITX motherboard, to NP905-B16C COM Express Compact, to NP951-B16C small form factor 3.5" SBC, to ES122-NP embedded system. As of 2009, DFI's capital increased to NTD 1.21 billion. And DFI launched a lineup including PT330-DRM microATX motherboard, PT631-IPM ATX motherboard, and HNVR320-PT embedded system based on Intel Core/Intel Pentium Processors (code name: Piketon). In 2010, DFI's capital increased to NTD 1.202 billion. DFI also launched a product line including CP100-NRM Mini-ITX motherboard, CP330-NRM microATX motherboard, CP908-B COM Express Compact, and ST101-CP embedded system based on Intel Core/Intel® Celeron® Processors with Mobile Intel QM57 Chipset (code name: Calpella).

DFI also launched system-on-module Qseven, QB700-B + Q7951, which was powered by Intel Atom E600 series processors (code name: Queensbay). In the end of 2010, DFI launched LR100-N18D/S/M Mini-ITX motherboard, LR905-B18D/S/M COM Express, and EC200/210/220/221 embedded system, which were based on

Intel 960 Series Chipsets (code name: Crestline), including different form factors consisting of SR100-L20C Mini-ITX motherboard and SR330-L microATX motherboard. In the same year, DFI also launched a product line based on Intel 945P Chipsets (code name: Lakeport), covering different form factors like G7L331-B microATX motherboard and LT600-D ATX motherboard. As of 2007, DFI's capital increased to NTD1.14 billion as well as a 65.77% equity of DFI-ITOX with acquisition cost of NTD 234 million. To guarantee exceptional quality and reliability of products under rigorous quality standards, DFI's products were approved by QC080000, WASO14001, and Green Partner certifications in 2007. DFI launched a product line based on Intel G41 Chipsets (code name: Eagle Lake), inclusive of EL109-N Mini-ITX motherboard, EL339-B microATX motherboard, and EL620-C ATX motherboard, as well as HNVR320-EL embedded system. In 2007, DFI also released a product line based on Intel Q35 Chipsets (code name: Bearlake), ranging from BL100-NE/PE Mini-ITX motherboard, to BL330-B microATX motherboard, to BL631-D ATX motherboard, As of 2008, DFI's capital increased to NTD 1.19 billion, acquiring 100% equity of YAN TONG TECHNOLOGYLTD with acquisition cost of NTD 187.26 million, as well as increasing the capital to DFI-Japan to JPY 280 million. In 2008, DFI released a product line based on Intel GM45 Chipsets (code name: Cantiga), ranging from CA900-B COM Express Basic, to small form factor CA230-BF Mini-DTX board, to CA101-D Mini-ITX motherboard, to CA331-P microATX motherboard. Furthermore, DFI launched a product series based on Intel Atom Processor Z500 series (code name: Silverthorne), offering from ML905-B11C/B16C COM Express, to small form factor ML936-B11C/B16C board, to CS910-ML embedded system. In the same year, DFI also kicked off a full range of product series which were based on Intel 945GSE Chipsets (code name: Navy Pier), covering from NP102-N16C Mini-ITX motherboard, to NP905-B16C COM Express Compact, to NP951-B16C small form factor 3.5" SBC, to ES122-NP embedded system. As of 2009, DFI's capital increased to NTD 1.21 billion. And DFI launched a lineup including PT330-DRM microATX motherboard, PT631-IPM ATX motherboard, and HNVR320-PT embedded system based on Intel Core/Intel Pentium Processors (code name: Piketon). In 2010, DFI's capital increased to NTD 1.202 billion. DFI also launched a product line including CP100-NRM Mini-ITX motherboard, CP330-NRM microATX motherboard, CP908-B COM Express Compact, and ST101-CP embedded system based on Intel Core/Intel® Celeron® Processors with Mobile Intel QM57 Chipset (code name: Calpella).

In May 2011, DFI's process-on-order factory in China was transformed into Sole proprietorship, which was capitalized with US$2.5 million. To expand its industrial computer business, DFI established a system engineering department to fulfill highly dedicated researches and design developments for the future. In 2012, DFI launched a product line based on Intel Atom® Processor D2550/N2800 (code name: Cedar Trail), including Mini-ITX form factor motherboard CD101-N, COM Express Compact CD905-B, 3.5" SBC motherboard CD951, and embedded system DS910-CD. On June 4, 2014, DFI established Yan Ying Hao Trading Co. Ltd.in ShenZhen, and started to develop business in the China region. To accommodate increasing growth and expansion, DFI relocated its corporate headquarter to Farglory U-Town building in New Taipei City. In 2016, DFI has released Qualcomm-based motherboard and medical industrial computer that dedicate itself to various fields and expand its business with different platforms. DFI has joined Qisda/BenQ Group. In the second half year of 2018, DFI has added the new SMT line to the factory to scale up its facilities and production capability.

DFI also launched system-on-module Qseven, QB700-B + Q7951, which was powered by Intel Atom E600 series processors (code name: Queensbay). In the end of 2010, DFI launched LR100-N18D/S/M Mini-ITX motherboard, LR905-B18D/S/M COM Express, and EC200/210/220/221 embedded system, which were based on

Intel 960 Series Chipsets (code name: Crestline), including different form factors consisting of SR100-L20C Mini-ITX motherboard and SR330-L microATX motherboard. In the same year, DFI also launched a product line based on Intel 945P Chipsets (code name: Lakeport), covering different form factors like G7L331-B microATX motherboard and LT600-D ATX motherboard. As of 2007, DFI's capital increased to NTD1.14 billion as well as a 65.77% equity of DFI-ITOX with acquisition cost of NTD 234 million. To guarantee exceptional quality and reliability of products under rigorous quality standards, DFI's products were approved by QC080000, WASO14001, and Green Partner certifications in 2007. DFI launched a product line based on Intel G41 Chipsets (code name: Eagle Lake), inclusive of EL109-N Mini-ITX motherboard, EL339-B microATX motherboard, and EL620-C ATX motherboard, as well as HNVR320-EL embedded system. In 2007, DFI also released a product line based on Intel Q35 Chipsets (code name: Bearlake), ranging from BL100-NE/PE Mini-ITX motherboard, to BL330-B microATX motherboard, to BL631-D ATX motherboard, As of 2008, DFI's capital increased to NTD 1.19 billion, acquiring 100% equity of YAN TONG TECHNOLOGYLTD with acquisition cost of NTD 187.26 million, as well as increasing the capital to DFI-Japan to JPY 280 million. In 2008, DFI released a product line based on Intel GM45 Chipsets (code name: Cantiga), ranging from CA900-B COM Express Basic, to small form factor CA230-BF Mini-DTX board, to CA101-D Mini-ITX motherboard, to CA331-P microATX motherboard. Furthermore, DFI launched a product series based on Intel Atom Processor Z500 series (code name: Silverthorne), offering from ML905-B11C/B16C COM Express, to small form factor ML936-B11C/B16C board, to CS910-ML embedded system. In the same year, DFI also kicked off a full range of product series which were based on Intel 945GSE Chipsets (code name: Navy Pier), covering from NP102-N16C Mini-ITX motherboard, to NP905-B16C COM Express Compact, to NP951-B16C small form factor 3.5" SBC, to ES122-NP embedded system. As of 2009, DFI's capital increased to NTD 1.21 billion. And DFI launched a lineup including PT330-DRM microATX motherboard, PT631-IPM ATX motherboard, and HNVR320-PT embedded system based on Intel Core/Intel Pentium Processors (code name: Piketon). In 2010, DFI's capital increased to NTD 1.202 billion. DFI also launched a product line including CP100-NRM Mini-ITX motherboard, CP330-NRM microATX motherboard, CP908-B COM Express Compact, and ST101-CP embedded system based on Intel Core/Intel® Celeron® Processors with Mobile Intel QM57 Chipset (code name: Calpella).

DFI also launched system-on-module Qseven, QB700-B + Q7951, which was powered by Intel Atom E600 series processors (code name: Queensbay). In the end of 2010, DFI launched LR100-N18D/S/M Mini-ITX motherboard, LR905-B18D/S/M COM Express, and EC200/210/220/221 embedded system, which were based on

As of 2012, DFI stopped consumer product line and no longer produced high-end gamer boards such as the LanParty series for end users

Emergency psychiatry:2923321

Individuals may arrive in psychiatric emergency service settings through their own voluntary request, a referral from another health professional, or through involuntary commitment. Care of patients requiring psychiatric intervention usually encompasses crisis stabilization of many serious and potentially life-threatening conditions which could include acute or chronic mental disorders or symptoms similar to those conditions.

Emergency psychiatry:2923321

As of 2000, the World Health Organization estimated one million suicides in the world each year. There are countless more suicide attempts. Psychiatric emergency service settings exist to treat the mental disorders associated with an increased risk of completed suicide or suicide attempts. Mental health professionals in these settings are expected to predict acts of violence patients may commit against themselves (or others), even though the complex factors leading to a suicide can stem from many sources, including psychosocial, biological, interpersonal, anthropological, and religious. These mental health professionals will use any resources available to them to determine risk factors, make an overall assessment, and decide on any necessary treatment.

Emergency psychiatry is the clinical application of psychiatry in emergency settings. Conditions requiring psychiatric interventions may include attempted suicide, substance abuse, depression, psychosis, violence or other rapid changes in behavior. Psychiatric emergency services are rendered by professionals in the fields of medicine, nursing, psychology and social work. The demand for emergency psychiatric services has rapidly increased throughout the world since the 1960s, especially in urban areas. Care for patients in situations involving emergency psychiatry is complex.

Emergency psychiatry:2923321

Emergency psychiatry is the clinical application of psychiatry in emergency settings. Conditions requiring psychiatric interventions may include attempted suicide, substance abuse, depression, psychosis, violence or other rapid changes in behavior. Psychiatric emergency services are rendered by professionals in the fields of medicine, nursing, psychology and social work. The demand for emergency psychiatric services has rapidly increased throughout the world since the 1960s, especially in urban areas. Care for patients in situations involving emergency psychiatry is complex.

Patient receive emergency services often on a time limited basis such as 24 or 72 hours. After this time, and sometimes earlier, the staff must decide the next place for the patient to receive services. This is referred to as disposition. This is one of the essential features of emergency psychiatry.

Individuals may arrive in psychiatric emergency service settings through their own voluntary request, a referral from another health professional, or through involuntary commitment. Care of patients requiring psychiatric intervention usually encompasses crisis stabilization of many serious and potentially life-threatening conditions which could include acute or chronic mental disorders or symptoms similar to those conditions.

Emergency psychiatry:2923321

Individuals may arrive in psychiatric emergency service settings through their own voluntary request, a referral from another health professional, or through involuntary commitment. Care of patients requiring psychiatric intervention usually encompasses crisis stabilization of many serious and potentially life-threatening conditions which could include acute or chronic mental disorders or symptoms similar to those conditions.

Electroconvulsive therapy is a controversial form of treatment which cannot be involuntarily applied in psychiatric emergency service settings. Instances wherein a patient is depressed to such a severe degree that the patient cannot be stopped from hurting himself or herself or when a patient refuses to swallow, eat or drink medication, electroconvulsive therapy could be suggested as a therapeutic alternative. While preliminary research suggests that electroconvulsive therapy may be an effective treatment for depression, it usually requires a course of six to twelve sessions of convulsions lasting at least 20 seconds for those antidepressant effects to occur.

Another common cause of psychotic symptoms is substance intoxication. These acute symptoms may resolve after a period of observation or limited psychopharmacological treatment. However the underlying issues, such as substance dependence or abuse, is difficult to treat in the emergency department, as it is a long term condition. Both acute alcohol intoxication as well as other forms of substance abuse can require psychiatric interventions. Acting as a depressant of the central nervous system, the early effects of alcohol are usually desired for and characterized by increased talkativeness, giddiness, and a loosening of social inhibitions. Besides considerations of impaired concentration, verbal and motor performance, insight, judgment and short term memory loss which could result in behavioral change causing injury or death, levels of alcohol below 60 milligrams per deciliter of blood are usually considered non-lethal. However, individuals at 200 milligrams per deciliter of blood are considered grossly intoxicated and concentration levels at 400 milligrams per deciliter of blood are lethal, causing complete anesthesia of the respiratory system.

Patients may also be treated for substance abuse following the administration of psychoactive substances containing amphetamine, caffeine, tetrahydrocannabinol, cocaine, phencyclidines, or other inhalants, opioids, sedatives, hypnotics, anxiolytics, psychedelics, dissociatives and deliriants. Clinicians assessing and treating substance abusers must establish therapeutic rapport to counter denial and other negative attitudes directed towards treatment. In addition, the clinician must determine substances used, the route of administration, dosage, and time of last use to determine the necessary short and long term treatments. An appropriate choice of treatment setting must also be determined. These settings may include outpatient facilities, partial hospitals, residential treatment centers, or hospitals. Both the immediate and long term treatment and setting is determined by the severity of dependency and seriousness of physiological complications arising from the abuse.

Another common cause of psychotic symptoms is substance intoxication. These acute symptoms may resolve after a period of observation or limited psychopharmacological treatment. However the underlying issues, such as substance dependence or abuse, is difficult to treat in the emergency department, as it is a long term condition. Both acute alcohol intoxication as well as other forms of substance abuse can require psychiatric interventions. Acting as a depressant of the central nervous system, the early effects of alcohol are usually desired for and characterized by increased talkativeness, giddiness, and a loosening of social inhibitions. Besides considerations of impaired concentration, verbal and motor performance, insight, judgment and short term memory loss which could result in behavioral change causing injury or death, levels of alcohol below 60 milligrams per deciliter of blood are usually considered non-lethal. However, individuals at 200 milligrams per deciliter of blood are considered grossly intoxicated and concentration levels at 400 milligrams per deciliter of blood are lethal, causing complete anesthesia of the respiratory system.

Emergency psychiatry:2923321

Beyond the dangerous behavioral changes that occur after the consumption of certain amounts of alcohol, idiosyncratic intoxication could occur in some individuals even after the consumption of relatively small amounts of alcohol. Episodes of this impairment usually consist of confusion, disorientation, delusions and visual hallucinations, increased aggressiveness, rage, agitation and violence. Chronic alcoholics may also suffer from alcoholic hallucinosis, wherein the cessation of prolonged drinking may trigger auditory hallucinations. Such episodes can last for a few hours or an entire week. Antipsychotics are often used to treat these symptoms.

Patients may also be treated for substance abuse following the administration of psychoactive substances containing amphetamine, caffeine, tetrahydrocannabinol, cocaine, phencyclidines, or other inhalants, opioids, sedatives, hypnotics, anxiolytics, psychedelics, dissociatives and deliriants. Clinicians assessing and treating substance abusers must establish therapeutic rapport to counter denial and other negative attitudes directed towards treatment. In addition, the clinician must determine substances used, the route of administration, dosage, and time of last use to determine the necessary short and long term treatments. An appropriate choice of treatment setting must also be determined. These settings may include outpatient facilities, partial hospitals, residential treatment centers, or hospitals. Both the immediate and long term treatment and setting is determined by the severity of dependency and seriousness of physiological complications arising from the abuse.

Beyond the dangerous behavioral changes that occur after the consumption of certain amounts of alcohol, idiosyncratic intoxication could occur in some individuals even after the consumption of relatively small amounts of alcohol. Episodes of this impairment usually consist of confusion, disorientation, delusions and visual hallucinations, increased aggressiveness, rage, agitation and violence. Chronic alcoholics may also suffer from alcoholic hallucinosis, wherein the cessation of prolonged drinking may trigger auditory hallucinations. Such episodes can last for a few hours or an entire week. Antipsychotics are often used to treat these symptoms.

Collateral information or parallel information is information obtained from family, friends or treatment providers of the patient. Some jurisdictions require consent from the patient to obtain this information while others do not. For example, with a patient who is thought to be paranoid about people following him or spying on him, this information can be helpful discern if these thoughts are more or less likely to be based in reality. Past episodes of suicide attempts or violent behavior can be confirmed or disproven.

Patients may also be treated for substance abuse following the administration of psychoactive substances containing amphetamine, caffeine, tetrahydrocannabinol, cocaine, phencyclidines, or other inhalants, opioids, sedatives, hypnotics, anxiolytics, psychedelics, dissociatives and deliriants. Clinicians assessing and treating substance abusers must establish therapeutic rapport to counter denial and other negative attitudes directed towards treatment. In addition, the clinician must determine substances used, the route of administration, dosage, and time of last use to determine the necessary short and long term treatments. An appropriate choice of treatment setting must also be determined. These settings may include outpatient facilities, partial hospitals, residential treatment centers, or hospitals. Both the immediate and long term treatment and setting is determined by the severity of dependency and seriousness of physiological complications arising from the abuse.

Another common cause of psychotic symptoms is substance intoxication. These acute symptoms may resolve after a period of observation or limited psychopharmacological treatment. However the underlying issues, such as substance dependence or abuse, is difficult to treat in the emergency department, as it is a long term condition. Both acute alcohol intoxication as well as other forms of substance abuse can require psychiatric interventions. Acting as a depressant of the central nervous system, the early effects of alcohol are usually desired for and characterized by increased talkativeness, giddiness, and a loosening of social inhibitions. Besides considerations of impaired concentration, verbal and motor performance, insight, judgment and short term memory loss which could result in behavioral change causing injury or death, levels of alcohol below 60 milligrams per deciliter of blood are usually considered non-lethal. However, individuals at 200 milligrams per deciliter of blood are considered grossly intoxicated and concentration levels at 400 milligrams per deciliter of blood are lethal, causing complete anesthesia of the respiratory system.

Patients may also be treated for substance abuse following the administration of psychoactive substances containing amphetamine, caffeine, tetrahydrocannabinol, cocaine, phencyclidines, or other inhalants, opioids, sedatives, hypnotics, anxiolytics, psychedelics, dissociatives and deliriants. Clinicians assessing and treating substance abusers must establish therapeutic rapport to counter denial and other negative attitudes directed towards treatment. In addition, the clinician must determine substances used, the route of administration, dosage, and time of last use to determine the necessary short and long term treatments. An appropriate choice of treatment setting must also be determined. These settings may include outpatient facilities, partial hospitals, residential treatment centers, or hospitals. Both the immediate and long term treatment and setting is determined by the severity of dependency and seriousness of physiological complications arising from the abuse.

Other treatment methods may be used in psychiatric emergency service settings. Brief psychotherapy can be used to treat acute conditions or immediate problems as long as the patient understands his or her issues are psychological, the patient trusts the physician, the physician can encourage hope for change, the patient has motivation to change, the physician is aware of the psychopathological history of the patient, and the patient understands that their confidentiality will be respected. The process of brief therapy under emergency psychiatric conditions includes the establishment of a primary complaint from the patient, realizing psychosocial factors, formulating an accurate representation of the problem, coming up with ways to solve the problem, and setting specific goals. The information gathering aspect of brief psychotherapy is therapeutic because it helps the patient place his or her problem in the proper perspective. If the physician determines that deeper psychotherapy sessions are required, he or she can transition the patient out of the emergency setting and into an appropriate clinic or center.

The staff will need to determine if the patient needs to be admitted to a psychiatric inpatient facility or if they can be safely discharged to the community after a period of observation and/or brief treatment. Initial emergency psychiatric evaluations usually involve patients who are acutely agitated, paranoid, or who are suicidal. Initial evaluations to determine admission and interventions are designed to be as therapeutic as possible.

Involuntary commitment, or sectioning, refers to situations where police officers, health officers, or health professionals classify an individual as dangerous to themselves, others, gravely disabled, or mentally ill according to the applicable government law for the region. After an individual is transported to a psychiatric emergency service setting, a preliminary professional assessment is completed which may or may not result in involuntary treatment. Some patients may be discharged shortly after being brought to psychiatric emergency services while others will require longer observation and the need for continued involuntary commitment will exist. While some patients may initially come voluntarily, it may be realized that they pose a risk to themselves or others and involuntary commitment may be initiated at that point.

The staff will need to determine if the patient needs to be admitted to a psychiatric inpatient facility or if they can be safely discharged to the community after a period of observation and/or brief treatment. Initial emergency psychiatric evaluations usually involve patients who are acutely agitated, paranoid, or who are suicidal. Initial evaluations to determine admission and interventions are designed to be as therapeutic as possible.

Since the 1960s, the demand for emergency psychiatric services has endured a rapid growth due to deinstitutionalization both in Europe and the United States. Deinstitutionalization, in some locations, has resulted in a larger number of severely mentally ill people living in the community. There have been increases in the number of medical specialties, and the multiplication of transitory treatment options, such as psychiatric medication. The actual number of psychiatric emergencies has also increased significantly, especially in psychiatric emergency service settings located in urban areas.

Involuntary commitment, or sectioning, refers to situations where police officers, health officers, or health professionals classify an individual as dangerous to themselves, others, gravely disabled, or mentally ill according to the applicable government law for the region. After an individual is transported to a psychiatric emergency service setting, a preliminary professional assessment is completed which may or may not result in involuntary treatment. Some patients may be discharged shortly after being brought to psychiatric emergency services while others will require longer observation and the need for continued involuntary commitment will exist. While some patients may initially come voluntarily, it may be realized that they pose a risk to themselves or others and involuntary commitment may be initiated at that point.

In some locations, such as the United States, voluntary hospitalizations are outnumbered by involuntary commitments partly due to the fact that insurance tends not to pay for hospitalization unless an imminent danger exists to the individual or community. In addition, psychiatric emergency service settings admit approximately one third of patients from assertive community treatment centers. Therefore, patients who are not admitted will be referred to services in the community.

Involuntary commitment, or sectioning, refers to situations where police officers, health officers, or health professionals classify an individual as dangerous to themselves, others, gravely disabled, or mentally ill according to the applicable government law for the region. After an individual is transported to a psychiatric emergency service setting, a preliminary professional assessment is completed which may or may not result in involuntary treatment. Some patients may be discharged shortly after being brought to psychiatric emergency services while others will require longer observation and the need for continued involuntary commitment will exist. While some patients may initially come voluntarily, it may be realized that they pose a risk to themselves or others and involuntary commitment may be initiated at that point.

Incidents of physical abuse, sexual abuse or rape can result in dangerous outcomes to the victim of the criminal act. Victims may suffer from extreme anxiety, fear, helplessness, confusion, eating or sleeping disorders, hostility, guilt and shame. Managing the response usually encompasses coordinating psychological, medical and legal considerations. Dependent upon legal requirements in the region, mental health professionals may be required to report criminal activity to a police force. Mental health professionals will usually gather identifying data during the initial assessment and refer the patient, if necessary, to receive medical treatment. Medical treatment may include a physical examination, collection of medicolegal evidence, and determination of the risk of pregnancy, if applicable.

In some locations, such as the United States, voluntary hospitalizations are outnumbered by involuntary commitments partly due to the fact that insurance tends not to pay for hospitalization unless an imminent danger exists to the individual or community. In addition, psychiatric emergency service settings admit approximately one third of patients from assertive community treatment centers. Therefore, patients who are not admitted will be referred to services in the community.

The staff will need to determine if the patient needs to be admitted to a psychiatric inpatient facility or if they can be safely discharged to the community after a period of observation and/or brief treatment. Initial emergency psychiatric evaluations usually involve patients who are acutely agitated, paranoid, or who are suicidal. Initial evaluations to determine admission and interventions are designed to be as therapeutic as possible.

In some locations, such as the United States, voluntary hospitalizations are outnumbered by involuntary commitments partly due to the fact that insurance tends not to pay for hospitalization unless an imminent danger exists to the individual or community. In addition, psychiatric emergency service settings admit approximately one third of patients from assertive community treatment centers. Therefore, patients who are not admitted will be referred to services in the community.

Overdoses, drug interactions, and dangerous reactions from psychiatric medications, especially antipsychotics, are considered psychiatric emergencies. Neuroleptic malignant syndrome is a potentially lethal complication of first or second generation antipsychotics. If untreated, neuroleptic malignant syndrome can result in fever, muscle rigidity, confusion, unstable vital signs, or even death. Serotonin syndrome can result when selective serotonin reuptake inhibitors or monoamine oxidase inhibitors mix with buspirone. Severe symptoms of serotonin syndrome include hyperthermia, delirium, and tachycardia that may lead to shock. Often patients with severe general medical symptoms, such as unstable vital signs, will be transferred to a general medical emergency department or medicine service for increased monitoring.

Weihai:1241716

Between 1898 and 1930, the city was part of the British leased territory of Weihaiwei; during this time, the city itself was known as Port Edward and served as the capital of Weihaiwei.

Weihai:1241716

The prefecture-level city of Weihai administers four county-level divisions, including two districts and two county-level cities.

Weihai (), formerly called Weihaiwei (), is a prefecture-level city and major seaport in easternmost Shandong province. It borders Yantai to the west and the Yellow Sea to the east, and is the closest Chinese city to South Korea.

Weihai's population was 2,804,771 as of the 2010 census. Amongst them, 844,310 lived in the current built-up ("metro") area (Huancui district) even though Wendeng district is soon being conurbated. Rongcheng, a county-level city within Weihai, has a built up area with 714,355 inhabitants. A subway is planned with 4 lines and route length to link all city districts. The first phase, Line 1 and 2 is planned for 2025.

Weihai (), formerly called Weihaiwei (), is a prefecture-level city and major seaport in easternmost Shandong province. It borders Yantai to the west and the Yellow Sea to the east, and is the closest Chinese city to South Korea.

In 1938, the Roman Catholic Independent Mission of Weihai was promoted to Apostolic Prefecture of Weihai but it has been vacant (dormant) since 1970. Weihaiwei was occupied by the Japanese from 1938 to 1945. There was a withdrawal of most British forces and supplies from Liugong Island, and finally a Japanese military landing and occupation of the island in 1940.

Weihai's population was 2,804,771 as of the 2010 census. Amongst them, 844,310 lived in the current built-up ("metro") area (Huancui district) even though Wendeng district is soon being conurbated. Rongcheng, a county-level city within Weihai, has a built up area with 714,355 inhabitants. A subway is planned with 4 lines and route length to link all city districts. The first phase, Line 1 and 2 is planned for 2025.

Weihai (), formerly called Weihaiwei (), is a prefecture-level city and major seaport in easternmost Shandong province. It borders Yantai to the west and the Yellow Sea to the east, and is the closest Chinese city to South Korea.

Weihai's population was 2,804,771 as of the 2010 census. Amongst them, 844,310 lived in the current built-up ("metro") area (Huancui district) even though Wendeng district is soon being conurbated. Rongcheng, a county-level city within Weihai, has a built up area with 714,355 inhabitants. A subway is planned with 4 lines and route length to link all city districts. The first phase, Line 1 and 2 is planned for 2025.

Weihaiwei was under British rule from 1 July 1898, under lease agreement with the Chinese empire, until 1930, with 'Port Edward' (Weihaiwei city) serving as the capital. A Royal Navy base was built on Liugong Island. Weihaiwei became a special administrative region after it was returned to the Republic of China on 1 October 1930, but Liugong Island and its facilities were leased back to the U.K. until 1940.

Between 1898 and 1930, the city was part of the British leased territory of Weihaiwei; during this time, the city itself was known as Port Edward and served as the capital of Weihaiwei.

Weihai (), formerly called Weihaiwei (), is a prefecture-level city and major seaport in easternmost Shandong province. It borders Yantai to the west and the Yellow Sea to the east, and is the closest Chinese city to South Korea.

Between 1898 and 1930, the city was part of the British leased territory of Weihaiwei; during this time, the city itself was known as Port Edward and served as the capital of Weihaiwei.

Campuses of Shandong University, Harbin Institute of Technology, Beijing Jiaotong University, Harbin University of Science and Technology, as well as Shandong Jiaotong University are located in Weihai.